Table 1.
Characteristic | N (%) |
---|---|
Sex | |
Male | 19 (45) |
Female | 23 (55) |
Age (years) | |
Median | 60 |
Range | 36 to 79 |
Race/ethnicity | |
Caucasian | 37 (88) |
African American | 3 (7) |
Other | 2 (5) |
ECOG performance status | |
0 | 15 (36) |
1 | 27 (64) |
Prior adjuvant therapy | 2 (5) |
Gemcitabine-baseda | 1 (50) |
Chemoradiationb | 1 (50) |
Disease stage | |
III | 2 (5) |
IV | 40 (95) |
Site of metastasis (N = 40) | |
Liver only | 29 (73) |
Liver + other | 2 (5) |
Other only | 9 (23) |
CA19-9 | |
Normal (≤37 U/ml) | 6 (14) |
Elevated (>37 U/ml) | 36 (86) |
Albumin | |
Normal (≥3.4 g/dl) | 28 (67) |
Low (<3.4 g/dl) | 14 (33) |
aPatients developed recurrence/metastases while on a clinical trial of gemcitabine ± Saccharomyces cerevisiae vaccine.
bPatients were treated on a clinical trial of 5-FU, cisplatin, interferon-α, and radiation.